TOP TEN perturbations for 38898_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38898_at
Selected probe(set): 212229_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38898_at (212229_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
CML study 1 / B-CLL study 5
Relative Expression (log2-ratio):-3.7660904Number of Samples:75 / 441
| Experimental | CML study 1 |
| Bone marrow samples of patients with chronic myeloid leukemia (CML). | |
| Control | B-CLL study 5 |
| Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL). |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, sarcoma, NOS; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, fibromyxosarcoma; primary)
Relative Expression (log2-ratio):3.7137299Number of Samples:7 / 5
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, sarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, sarcoma, NOS of the soft tissue (subcutaneously implanted). | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, fibromyxosarcoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, fibromyxosarcoma of the soft tissue (subcutaneously implanted). |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, fibromyxosarcoma; primary)
Relative Expression (log2-ratio):3.667326Number of Samples:6 / 5
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, synovial sarcoma, spindle cell of the soft tissue (subcutaneously implanted). | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, fibromyxosarcoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, fibromyxosarcoma of the soft tissue (subcutaneously implanted). |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, fibromyxosarcoma; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, dedifferentiated liposarcoma; primary)
Relative Expression (log2-ratio):-3.5505972Number of Samples:5 / 5
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, fibromyxosarcoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, fibromyxosarcoma of the soft tissue (subcutaneously implanted). | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, dedifferentiated liposarcoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, dedifferentiated liposarcoma of the soft tissue (subcutaneously implanted). |
ovarian tumor study 16 / normal ovarian surface epithelial cell sample
Relative Expression (log2-ratio):-3.1135664Number of Samples:3 / 5
| Experimental | ovarian tumor study 16 |
| Human epithelial tumor cell samples from the ovary of patients with papillary serous carcinoma. Samples were derived by laser capture microdissection (LCM). | |
| Control | normal ovarian surface epithelial cell sample |
| Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue. |
R547 study 1 (24h) / vehicle (DMSO) treated DU145 cell sample
Relative Expression (log2-ratio):-3.0952244Number of Samples:2 / 4
| Experimental | R547 study 1 (24h) |
| Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:--- | |
| Control | vehicle (DMSO) treated DU145 cell sample |
| Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours. |
expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)
Relative Expression (log2-ratio):2.645976Number of Samples:8 / 2
| Experimental | expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary serous cystadenocarcinoma (NOS) of the ovary. | |
| Control | expO ovary cancer study 1 (dysgerminoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary. |
B-CLL study 5 / normal bone marrow sample
Relative Expression (log2-ratio):2.633707Number of Samples:441 / 74
| Experimental | B-CLL study 5 |
| Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL). | |
| Control | normal bone marrow sample |
| Non-leukemic and healthy bone marrow sample. |
phenobarbital study 3 (10000uM) / vehicle (medium) treated hepatocyte sample
Relative Expression (log2-ratio):-2.3590784Number of Samples:2 / 2
| Experimental | phenobarbital study 3 (10000uM) |
| Hepatocytes treated with compound: phenobarbital (10000uM; CHEMBL40) for 24 hours. ATC code: | |
| Control | vehicle (medium) treated hepatocyte sample |
| Hepatocytes treated with vehicle (medium) for 24 hours. |
pediatric septic shock study 3 (infant; subclass A) / normal blood sample (infant)
Relative Expression (log2-ratio):-2.2818651Number of Samples:8 / 17
| Experimental | pediatric septic shock study 3 (infant; subclass A) |
| Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses. | |
| Control | normal blood sample (infant) |
| Whole blood samples from infants (1 month – 1 year). Children who had a recent febrile illness (within 2 weeks), who recently used anti-inflammatory medications (within 2 weeks) or who had any history of chronic or acute disease associated with inflammation were excluded from the study. |